Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · N16837/S039

Artegraft Collagen Vascular Graft

LeMaitre Vascular, Inc. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONN16837/S039

What did the FDA approve?

FDA recorded approval of supplement N16837/S039 for LeMaitre Vascular, Inc.'s Artegraft Collagen Vascular Graft, a tissue graft of 6mm and greater under product code LXA in the cardiovascular specialty. The supplement is a Special (Immediate Track) submission with a stated reason of labeling change covering indications, instructions, shelf life, or tradename. As a supplement to the original PMA, it is not a new approval of the whole device system.

The source statement describes the approved change as a new warning and other labeling changes in the Instructions for Use. It does not identify the specific wording of the warning, which other labeling items changed, or the original PMA's initial scope. The stated purpose is the labeling change itself, not independent proof of safety or clinical effectiveness, and no such findings are reported in the supplied fields.

FDA approval order statement

Approval of a new warning and other labeling changes in the Instructions for Use for the Artegraft Collagen Vascular Graft
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Sep 4, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
N16837/S039
Regulatory pathway
PMA supplement
Product code
LXA
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Tissue graft of 6mm and greater.

Product code
LXA
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. N16837/S039 received

    Application receipt date recorded by FDA.

  2. N16837/S039 · FDA decision

    Special (Immediate Track)

Related devices and submissions

Explore the linked device profile

Other records with product code LXA

Product / regulatory recordCompanyPathwayDecision dateSource
LeMaitre Vascular, Inc.PMA supplementOct 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LeMaitre Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
63 Second Ave., Burlington, MA, 01803

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records